Research programme: siRNA therapeutics - General Research Laboratory/Sirnaomics

Drug Profile

Research programme: siRNA therapeutics - General Research Laboratory/Sirnaomics

Alternative Names: STP 503

Latest Information Update: 10 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator General Research Laboratory; Sirnaomics
  • Class Small interfering RNA
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; RNA interference; Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Prostate cancer

Most Recent Events

  • 08 Sep 2016 Preclinical trials in Breast cancer in France (Parenteral)
  • 10 Jul 2014 Research programme: siRNA therapeutics - General Research Laboratory/Sirnaomics is still in preclinical development for Prostate cancer and wounds in USA and China
  • 12 Mar 2008 Preclinical trials in Prostate cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top